Regenerative Medicine

These 2 Penny Stocks Could See Outsized Gains, Says Oppenheimer | 10/13/2020

Column: The California stem cell program’s $5.5-billion funding request might be its downfall The California Institute for Regenerative Medicine is seeking a new $5.5-billion infusion. It must go back to the drawing board. The route to cures was always more complex than the campaign led on, and none has yet emerged for those headline maladies. Meanwhile, CIRM has come almost to the end of its original $3-billion …

Insights on Wound Care Market within the Health Care Supplies Sector | Increase in Pet Ownership to Emerge as a Key Driver | Technavio | Business Wire | 10/13/2020

… and disposables Tubes Drapes Replaceable blades Nutritional and pharmaceutical solutions Prefilled syringes Anesthesia Empty syringes and needles Catheters, bandages, dressings, and similar products Therapy area Medication Renal care General surgery Urology surgery Gynecology surgery Regenerative medicine Robotic surgery Geography Americas Europe Asia Pacific (APAC) Rest of the world (RoW) Register for a free trial today and gain instant access to 17,000+ market research reports Technavio’s SUBSCRIPTION platform Vendor Landscape Technavio’s …

Follow Regenerative Medicine:    

Opinion: The Post’s recommendations on the 12 ballot propositions and Measure RR | 10/13/2020

… know Robin Hood is two words. You grammar cops, give us a break!) Prop. 14 wastes money Prop. 14 — No. It authorizes the sale of $5.5 billion in bonds for the California Institute of Regenerative Medicine , now that the agency has exhausted the original $3 billion it got from taxpayers 16 years ago. The original purpose of the agency known as CRIM was to fund fetal stem cell research because …

Polarityte (NASDAQ:PTE) Upgraded at Zacks Investment Research - TheOlympiaReport | 10/13/2020

Zacks Investment Research upgraded shares of Polarityte (NASDAQ:PTE) in a research report released on Saturday, Zacks.com reports. They currently have $1.25 price target on the stock. According to Zacks, “PolarityTE, Inc. creates regenerative medicine and provides tissue engineering platform. It develops and obtains regulatory approval for technology which utilizes a patient’s own tissue substrates for regeneration of skin, bone, muscle, cartilage and nerves. The product pipeline comprises SkinTE, OsteoTE …

Global Regenerative Medicine Market Strategy Framework, Revenue And Industry Forecasts Till, 2013-2019: Radiant Insights, Inc | 10/13/2020

Submitted by Douglus . The report ‘Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019’ reviews the latest trends in regenerative medicine with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract / Clinical / Commercial Research Organizations (CROs), government/academic organizations …

2020 Trending report on Regenerative Medicine Market Analysis | Growth | Size | Share | Trends | Insights | Forecast 2025 | 10/13/2020

Buy This Premium Report: https://www.eonmarketresearch.com/buy/50741 Research Objectives Of Regenerative Medicine Market: This report provides pin-point analysis for changing competitive dynamics It provides a forward-looking perspective on different factors driving or restraining the market growth It provides a six-year forecast assessed on the basis of how the market is predicted to grow It helps in understanding the key product segments and their future It provides …

Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa | Globe Newswire | 10/12/2020

… Should we expect more or less regulation? ” with the participation of panelists from the European Organization for Rare Diseases (EURORDIS), the European Medicines Agency (EMA) and the European Commission. Organized by the Alliance for Regenerative Medicine , the Cell & Gene Meeting on the Mesa is a five-day virtual conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past …

Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa Brussels Stock Exchange:BOTHE | Globe Newswire | 10/12/2020

… Should we expect more or less regulation? ” with the participation of panelists from the European Organization for Rare Diseases (EURORDIS), the European Medicines Agency (EMA) and the European Commission. Organized by the Alliance for Regenerative Medicine , the Cell & Gene Meeting on the Mesa is a five-day virtual conference featuring more than 120 dedicated company presentations by leading public and private companies, highlighting technical and clinical achievements over the past …

Postdoctoral Fellowship in Protein Design and Mammalian Synthetic Biology | 10/12/2020

… working at the cutting-edge of protein design and mammalian cell design. You will join a highly motivated team of synthetic biologists developing cell-based therapies and gene therapies, with a particular focus on regenerative medicine . Applicants should have completed their graduate studies in one or more of the following (or related) areas: Synthetic biology Systems biology Regenerative medicine Applicants that have experience in gene editing, computational protein modelling/design …

Stem Cell Scientist Jeanne Loring on hESC Research, Proposition 14 and California Stem Cell Agency | 10/12/2020

Editor’s Note: The following commentary concerning the California Institute for Regenerative Medicine (CIRM) and Proposition 14 was submitted to the California Stem Cell Report by Jeanne Loring , professor emeritus from the Scripps Research Institute and co-founder of Aspen Neuroscience, Inc. , of San Diego.) By Jeanne Loring “Long ago, when Bob (Klein) and Jeff (Sheehy) were both CIRM’s oversight board members, their arguments were legend. I was at the meetings …

BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa | PR Newswire | 10/12/2020

… ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 …

Age Rejuvenation, Formerly Tampa Rejuvenation, Expands Nationwide and Partners With Bella Aesthetics | 10/12/2020

… 2020 09:00 EDT TAMPA, Fla., October 12, 2020 (Newswire.com) - Tampa Rejuvenation eagerly announces that it is rebranding to Age Rejuvenation and plans to expand beyond the Tampa Bay area. Known for its high-quality regenerative medicine services, Age Rejuvenation is also pleased to announce a new partnership with Bella Aesthetics. The new identity and partnership leverages the company’s mission to revolutionize health and wellness, while also maintaining a focus on …

Regenerative Medicine Market Recent Industry Trends and Projected Industry Growth by 2027 Integra LifeSciences Corporation, Astellas Pharma Inc., Corline Biomedical AB | 10/12/2020

RSS Regenerative Medicine Market Recent Industry Trends and Projected Industry Growth by 2027 Integra LifeSciences Corporation, Astellas Pharma Inc., Corline Biomedical AB The increased incidence of chronic illnesses and genetic disorders and increased spending by governments are driving the demand for the market. Vancouver, BC – ( SBWIRE ) – 10/12/2020 – The new report titled ‘Global Regenerative Medicine Market ‘, published by Emergen Research, is methodically curated by our team of analysts, keeping readers’ understanding …

When it comes to arthritic bone spurs, stem cells hurt instead of heal | 10/12/2020

… progenitor cells promote healthy bone repair in other contexts, they are inappropriately activated to cause a pathological bony protuberance in the context of arthritis,” said Gage Crump, a professor of stem cell biology and regenerative medicine at USC. Crump is the paper’s co-corresponding author, along with Cosimo de Bari from the University of Aberdeen in the UK. Led by Crump and de Bari, an international team of scientists made …

ARM and NAMCP Publish Recommendations to Increase Patient Access in Joint Study, Roadmap for Navigating the Provider Side of Cell and Gene Therapy (CGT) Patient Access in US Managed Care | Globe Newswire | 10/12/2020

Washington, DC, Oct. 12, 2020 (GLOBE NEWSWIRE) – via NewMediaWire – Reducing payment and reimbursement barriers is the most important factor in driving provider uptake of cell and gene therapies, the Alliance for Regenerative Medicine (ARM) and the National Association of Managed Care Physicians (NAMCP) Medical Directors Institute concluded in a joint study announced today. The study – “Roadmap for Navigating the Provider Side of Cell and Gene Therapy Patient Access in U.S …

Cell Therapy Market to Reach $48.11 Bn, Globally, by 2027 at 25.6% CAGR: Allied Market Research | PR Newswire | 10/12/2020

… Report at: https://www.alliedmarketresearch.com/request-for-customization/5330?reqfor=covid Drivers, restraints, and opportunities- Technological advancements in the medical field, rise in number of cell therapies in clinical studies, and increase in adoption of regenerative medicine s fuel the growth of the market for global cell therapy. On the other hand, high costs of the therapy impede the growth to some extent. However, high growth potential in emerging markets is expected …

Pig Hearts Might be Used in Human Transplants by the End of 2021 | 10/12/2020

WRITTEN BY: Carmen Leitch A major problem hurdle in organ transplantation is a lack of healthy donors. For many years, scientists in the field of regenerative medicine have been trying to find new ways to create organs for transplant. Animals may be one source of new organs; pig hearts, for example, have long been studied as an option. A new review in Circulation has outlined genetic and pharmacological advancements that …

Biological Clock that Drives Embryological Development | 10/12/2020

… discovered the mechanism is based on how proteins are made and dismantled. The study, published in Science, could also help us understand how different mammals evolved from one another and help refine methods for regenerative medicine . Different development time-scales All mammals follow the same steps to grow from embryo to adult. This involves the same series of events, in the same sequence, using similar genes and molecular signals. However …

(Podcast) Functional Family Medicine SPOTLIGHT: Meet Dr. Daniel Stock | 10/12/2020

Dr. Dan Stock, A founding diplomate of the American Board of Clinical Lipidology, Dr. Stock is also a diplomate of the American Board of Anti-Aging and Regenerative Medicine . By We sit down with Dr. Daniel Stock, the Founding Physician at PureHealth Functional Family Medicine. Dr. Stock’s office is located in Noblesville, Indiana. After 18 years of being hospital-employed, Dr. Daniel Stock has opened the doors to his new …

Polarityte (NASDAQ:PTE) Raised to Buy at Zacks Investment Research - Ticker Report | 10/12/2020

… firm presently has a $1.25 price objective on the stock. Zacks Investment Research ‘s target price would suggest a potential upside of 15.74% from the company’s previous close. According to Zacks, “PolarityTE, Inc. creates regenerative medicine and provides tissue engineering platform. It develops and obtains regulatory approval for technology which utilizes a patient’s own tissue substrates for regeneration of skin, bone, muscle, cartilage and nerves. The product pipeline comprises SkinTE …

Flow Cytometry Standards Consortium | 10/12/2020

The National Institute of Standards and Technology (NIST), an agency of the United States Department of Commerce, in support of efforts to develop standards for regenerative medicine and advanced therapies, is establishing the Flow Cytometry Standards Consortium (“Consortium”). The Consortium will bring together stakeholders to identify and address measurement and standards needs related to flow cytometry used in the characterization and testing of cell and gene therapies. The Consortium efforts …

CIRM Bridges to Stem Cell Research and Therapy: The Bridge to Everywhere in biomedicine | 10/12/2020

… a fifth line treatment. Think about the improved quality-of-life for those who receive cell therapy instead of aggressive chemotherapy. Let the day-dream expand for a moment to include other areas of regenerative medicine on the horizon: genes, cells, and tissues working in concert with our own bodies to do what unhealthy cells are incapable of doing on their own. Insulin-producing cell therapy for diabetics, insulation of …

Analyzing Alpha Pro Tech (NYSE:APT) and COLLPLANT HOLDI/S (NYSE:CLGN) | 10/11/2020

… more affordable of the two stocks. Summary Alpha Pro Tech beats COLLPLANT HOLDI/S on 9 of the 13 factors compared between the two stocks. COLLPLANT HOLDI/S Company Profile CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada …

Should California invest $5.5 billion more into promising stem cell research? | The Mercury News | 10/11/2020

… can discern the time on her cell phone, the colors of kitchen cups and the faces of her family. In addition to these and more than 60 other clinical trials, the California Institute for Regenerative Medicine (CIRM) created under Proposition 71 has led to about 3,000 peer-reviewed research papers and 974 patents or patent applications. It has helped bankroll 12 elegant research facilities, donating $43 million to Stanford for …

Treating the Equine Athlete | 10/11/2020

Diplomate – American College of Veterinary Surgeons James Law Professor of Large Animal Surgery Associate Chair for the Department of Clinical Sciences Committee on Research and Graduate Education Cornell Equine Park Faculty Director Fortier Comparative Orthopedics and Regenerative Medicine Research Laboratory A leader in advancing our knowledge of musculoskeletal disease and injury The Fortier Comparative Orthopedics and Regenerative Medicine Research Laboratory is a leader in advancing our knowledge of the pathogenesis …

COVID-19

Opinion: Prop. 14 provides health, economic benefits for California | The Mercury News | 9/20/2020

… have been lost, too many Californians are out of work, and our state budget is beyond strained. The toll of COVID-19 is emblematic of the cost and devastation associated with chronic disease — as it … when we passed Proposition 71, creating the California Institute for Regenerative Medicine (CIRM), a statewide stem cell research and therapy funding institute located here in Oakland. Since then, California has made great progress on advancing …

Oncology

Sumitomo Dainippon Pharma Oncology Presents Findings from Phase 1 Clinical Study Evaluating Investigational Agent Dubermatinib in Patients with Advanced Solid Tumors at ESMO 2020 Virtual Annual Congress | PR Newswire | 9/18/2020

PRNewswire/ – Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today presented new data from the ongoing Phase 1 study evaluating dubermatinib (TP-0903), an AXL kinase inhibitor, in patients with advanced solid … products in the Psychiatry & Neurology area, the Oncology area and Regenerative medicine/Cell therapy field, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma is based on the merger in 2005 between …

Gene Therapy

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020 | Globe Newswire | 9/17/2020

… with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in … indication anticipated in the US during 2021. Novartis received FDA Regenerative Medicine Advanced Therapy (RMAT) designation earlier in the year. The RMAT programme was created to expedite the development and review of regenerative medicine therapies …

Food and Drug Administration

FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) | PR Newswire | 9/16/2020

… this life-threatening syndrome. The hCT-MSCs are manufactured in the Robertson GMP Cell Manufacturing Laboratory at Duke . The U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) Application, and Dr. Kurtzberg … Duke Health and a leader in transplantation, cell therapy, and regenerative medicine in children. Clinical sites include Duke University ( Durham, NC ), Children’s Healthcare of Atlanta ( Atlanta, GA ), New York Medical College ( Valhalla, NY ), and others …

Children's Health

FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) | PR Newswire | 9/16/2020

regenerative medicine in children. Clinical sites include Duke University ( Durham, NC ), Children’s Healthcare of Atlanta ( Atlanta, GA ), New York Medical College ( Valhalla, NY ), and others as cases occur. “We hope this is just the beginning of our ability to support the development of cell therapies to treat COVID-19 Related Multisystem Inflammatory Syndrome in Children,” said Dr. Robin Smith, president of the Cura Foundation. “As students across the country return …

Cardiology

Mutsuki Takano Was Appointed as CFO at Heartseed | Business Wire | 9/15/2020

regenerative medicine developed by Prof. Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo. Heartseed has original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purification, cell delivery and iPSC production, and has raised more than USD 38 million. Company Name: Heartseed Inc. Established: November 30, 2015 President: Keiichi Fukuda Headquarter: Art Complex Center 302, Daikyocho 12-9, Shinjuku-ku, Tokyo …

Ohio State University

Vizgen Taps Akoya Biosciences Executive Terry Lo As New President and CEO | PR Newswire | 9/14/2020

… of Business, an MS in Microbiology from Virginia Tech , and dual BS degrees in Molecular Genetics and Psychology from The Ohio State University. “I’m excited to take the helm at Vizgen to work together with … medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. For more information, go to www.vizgen.com , connect on social media @Twitter , @LinkedIn and Facebook , and join the MERFISH Group at: https://bit.ly/merfishgroup …

Virginia Tech

Vizgen Taps Akoya Biosciences Executive Terry Lo As New President and CEO | PR Newswire | 9/14/2020

… new markets. He holds an MBA from the University of Chicago Booth School of Business, an MS in Microbiology from Virginia Tech , and dual BS degrees in Molecular Genetics and Psychology from The Ohio State … medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. For more information, go to www.vizgen.com , connect on social media @Twitter , @LinkedIn and Facebook , and join the MERFISH Group at: https://bit.ly/merfishgroup …

Community Health

A Carbohydrate Beverage Reduces Monocytes Expressing TLR4 in Children with Overweight or Obesity. | National Institutes of Health | 9/11/2020

… Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA. 2 Department of Pediatrics, University of Arizona College of Medicine, Tucson, AZ, USA. 3 School of Human Kinetics, Brain and Mind Institute, Centre on Neuromuscular Disease, University of Ottawa, Ottawa, ON, Canada. 4 Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. PMID: 31825075 Format Abstract Background: Childhood obesity is increasing, with about one-third of children overweight …

National Institutes of Health

Aspen Valley Hospital and The Steadman Clinic Form Strategic Partnership | Globe Newswire | 9/9/2020

… support the training of future orthopaedic surgeons and development of technologies to advance musculoskeletal health. SPRI has been awarded six National Institutes of Health (NIH) grants, two Department of Defense (DoD) contracts, and is underway … Rehabilitation Thos A. Evans, MD: Orthopaedic Interventionist of Spine & Joint, Regenerative Medicine Specialist Jonathan A. Godin, MD, MBA: Shoulder, Knee, Hip and Sports Medicine Surgeon Tom R. Hackett, MD: Complex Knee, Shoulder and Elbow Surgeon …

NIH

Aspen Valley Hospital and The Steadman Clinic Form Strategic Partnership | Globe Newswire | 9/9/2020

… future orthopaedic surgeons and development of technologies to advance musculoskeletal health. SPRI has been awarded six National Institutes of Health (NIH) grants, two Department of Defense (DoD) contracts, and is underway on five groundbreaking clinical … Rehabilitation Thos A. Evans, MD: Orthopaedic Interventionist of Spine & Joint, Regenerative Medicine Specialist Jonathan A. Godin, MD, MBA: Shoulder, Knee, Hip and Sports Medicine Surgeon Tom R. Hackett, MD: Complex Knee, Shoulder and Elbow Surgeon …

Biotech

Global Stem Cells Industry | Globe Newswire | 9/9/2020

… Cryo-Cell International Inc. Cytori Therapeutics Inc. ESI BIO Gamida Cell Ltd. Holostem Terapie Avanzate International Stem Cell Corp. Kangstem Biotech. Ltd. Lonza Group Ltd. Mesoblast Ltd. Neuralstem Inc. Nuvasive Inc. OncoMed Pharmaceuticals Inc. Osiris … by Region/Country in Percentage: 2020 VS 2027 Table 7: Regenerative Medicine (Application) Global Market Estimates & Forecasts in US$ Million by Region/Country: 2020-2027 Table 8: Regenerative Medicine (Application) Market Share Breakdown by Region/Country …

Biopharma

Global Stem Cells Industry | Globe Newswire | 9/9/2020

… A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, apceth Biopharma GmbH Athersys Inc. AVIVA BioSciences Corporation BioE Inc. Bone Therapeutics SA Cesca Therapeutics Inc … by Region/Country in Percentage: 2020 VS 2027 Table 7: Regenerative Medicine (Application) Global Market Estimates & Forecasts in US$ Million by Region/Country: 2020-2027 Table 8: Regenerative Medicine (Application) Market Share Breakdown by Region/Country …

Health Tech

Bimini Health Tech Expands with European HQ | PR Newswire | 9/8/2020

Bimini Health Tech Expands with European HQ Appoints Mr. Xavier Migaud, Managing Director, EMEA News provided by Sep 08, 2020, 10:02 ET Share this article RENNES, France , Sept. 8, 2020 /PRNewswire/ – Bimini Health Tech has … region. Mr. Migaud has extensive experience in the field of regenerative medicine and has positively impacted the growth of autologous therapies such as fat transfer and platelet rich plasma. “Xavier is a natural leader and …

UC Davis

Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patients | PR Newswire | 9/8/2020

Regenerative Medicine (CIRM). Participating trial sites include Hackensack University Medical Center and Atlantic Health in New Jersey , MultiCare Health System in Washington State , Banner University Medical Center Phoenix in Arizona , the University of Arkansas in Arkansas , and UC Davis in California . The Principal Investigator is Corey Casper , M.D., MPH, of the Infectious Disease Research Institute (IDRI) ClinicalTrials.gov Identifier: NCT04365101 . “Through this collaboration with our partner sites, we were able to …

Medicaid

StimLabs, LLC. Announces Launch of Second Umbilical Cord Derived Product: Corplex™ P | PR Newswire | 8/27/2020

… available today. As of July 1, 2020 , both products have been granted Q Codes by the Centers for Medicare and Medicaid Services (CMS) under Q4232 (Corplex) and Q4231 (Corplex P). About Corplex P Corplex P … in 2015 with a desire to advance the state of regenerative medicine. Within a year of its inception, StimLabs built and certified an ISO Class 7 clean room facility, conceptualized and launched a suite of …

Medicare

StimLabs, LLC. Announces Launch of Second Umbilical Cord Derived Product: Corplex™ P | PR Newswire | 8/27/2020

… derivative, is available today. As of July 1, 2020 , both products have been granted Q Codes by the Centers for Medicare and Medicaid Services (CMS) under Q4232 (Corplex) and Q4231 (Corplex P). About Corplex P … in 2015 with a desire to advance the state of regenerative medicine. Within a year of its inception, StimLabs built and certified an ISO Class 7 clean room facility, conceptualized and launched a suite of …

Centers for Medicare and Medicaid Services

StimLabs, LLC. Announces Launch of Second Umbilical Cord Derived Product: Corplex™ P | PR Newswire | 8/27/2020

… umbilical cord derivative, is available today. As of July 1, 2020 , both products have been granted Q Codes by the Centers for Medicare and Medicaid Services (CMS) under Q4232 (Corplex) and Q4231 (Corplex P). About … in 2015 with a desire to advance the state of regenerative medicine. Within a year of its inception, StimLabs built and certified an ISO Class 7 clean room facility, conceptualized and launched a suite of …

21st Century Cures Act

Steadman Philippon Research Institute (SPRI) Receives Multi-Million-Dollar Matching Grant from the National Institutes of Health | Globe Newswire | 8/20/2020

… ET Source: Steadman Philippon Research Institute VAIL, Colorado, Aug. 20, Steadman Philippon Research Institute (SPRI) has been granted the prestigious Regenerative Medicine Innovation Project Investigator-Initiated Clinical Trials award from the National Institutes of Health … disease, the United States Congress included a provision in the 21st Century Cures Act — a law passed in December 2016 to accelerate medical discovery and innovation — to support the NIH-established Regenerative Medicine Innovation Project …

Cures Act

Steadman Philippon Research Institute (SPRI) Receives Multi-Million-Dollar Matching Grant from the National Institutes of Health | Globe Newswire | 8/20/2020

… ET Source: Steadman Philippon Research Institute VAIL, Colorado, Aug. 20, Steadman Philippon Research Institute (SPRI) has been granted the prestigious Regenerative Medicine Innovation Project Investigator-Initiated Clinical Trials award from the National Institutes of Health … United States Congress included a provision in the 21st Century Cures Act — a law passed in December 2016 to accelerate medical discovery and innovation — to support the NIH-established Regenerative Medicine Innovation Project (RMIP). The …

Patient Safety

Steadman Philippon Research Institute (SPRI) Receives Multi-Million-Dollar Matching Grant from the National Institutes of Health | Globe Newswire | 8/20/2020

… ET Source: Steadman Philippon Research Institute VAIL, Colorado, Aug. 20, Steadman Philippon Research Institute (SPRI) has been granted the prestigious Regenerative Medicine Innovation Project Investigator-Initiated Clinical Trials award from the National Institutes of Health … adult stem cells while promoting the highest standards for protecting patient safety during the conduct of research. “This is a really great honor for SPRI,” said Dr. Huard, who first came to Vail in 2015 …

Clinical Research

Steadman Philippon Research Institute (SPRI) Receives Multi-Million-Dollar Matching Grant from the National Institutes of Health | Globe Newswire | 8/20/2020

… ET Source: Steadman Philippon Research Institute VAIL, Colorado, Aug. 20, Steadman Philippon Research Institute (SPRI) has been granted the prestigious Regenerative Medicine Innovation Project Investigator-Initiated Clinical Trials award from the National Institutes of Health … RMIP). The RMIP aims to accelerate the field by supporting clinical research on adult stem cells while promoting the highest standards for protecting patient safety during the conduct of research. “This is a really great …

Hematology

Stanford Children’s Health Appoints New Chief of Pediatric Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine | PR Newswire | 8/20/2020

PALO ALTO, Calif. , Aug. 20, 2020 /PRNewswire/ – Physician-scientist Tanja Gruber , MD, PhD, has been appointed Division Chief of Hematology, Oncology , and Stem Cell Transplantation and Regenerative Medicine in the Division of Pediatrics at the Stanford University School of Medicine , Associate Director for Childhood Cancer in the Stanford Cancer Institute , and Director of the Bass Center for Childhood Cancer and Blood Diseases at Stanford Children’s Health . Tanja Gruber, MD, PhD …

Medical Research

How do you separate scientifically sound stem cell therapies from scams? | STAT | 8/18/2020

… unproven therapies like stem cell treatments offer new hope. But how do you sort the scientifically legitimate from the dangerous? Regenerative medicine is a controversial field, still in its infancy. There are academic researchers and … informed decision,” said Sean Morrison, the director of the Children’s Medical Research Center at UT Southwestern and the chair of the International Society for Stem Cell Research public policy committee. The Wild West of information …

Genomics

Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research | Business Wire | 8/15/2020

genomics and specifically in the identification of the human genome which has radically transformed healthcare according to Prof. Gary Levy, chair, Edogawa NICHE awards committee ( www.edogawanicheprize.org ). Edogawa NICHE Prize was Instituted in 2018, by the Jinseisha trust, and the Nichi-In Centre for Regenerative Medicine (NCRM), which honours scientists or clinicians whose contributions lead to the development of prevention, diagnosis or treatment of any disease, through an inter-disciplinary approach …

United Therapeutics

CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant | PR Newswire | 9/21/2020

CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant English English Expanded collaboration combines CollPlant’s proprietary BioInk that is based on its recombinant human collagen (rhCollagen) technology and United Therapeutics’ regenerative medicine and organ manufacturing capabilities Collaboration aims to help reduce global organ shortages of kidney transplants and potentially save lives of millions of patients on kidney …

Boehringer Ingelheim

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020 | Globe Newswire | 9/17/2020

… into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it … indication anticipated in the US during 2021. Novartis received FDA Regenerative Medicine Advanced Therapy (RMAT) designation earlier in the year. The RMAT programme was created to expedite the development and review of regenerative medicine therapies …

Novartis

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020 | Globe Newswire | 9/17/2020

… ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim … indication anticipated in the US during 2021. Novartis received FDA Regenerative Medicine Advanced Therapy (RMAT) designation earlier in the year. The RMAT programme was created to expedite the development and review of regenerative medicine therapies …

AstraZeneca

OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020 | Globe Newswire | 9/17/2020

… potential gene and cell therapy products. Additionally, the Group has signed a 3-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford … indication anticipated in the US during 2021. Novartis received FDA Regenerative Medicine Advanced Therapy (RMAT) designation earlier in the year. The RMAT programme was created to expedite the development and review of regenerative medicine therapies …

Medtronic

Regenerative tissue developer Aziyo Biologics files for $58M IPO | FierceBiotech | 9/16/2020

Regenerative medicine company Aziyo Biologics has filed for a $57.5 million Nasdaq IPO, with plans to expand its marketing and clinical development programs. With a focus on tissue-based products for patients receiving medical device implants, the company has previously partnered up with Medtronic, Boston Scientific, Biotronik and more—with its core, FDA-cleared offerings centered around cardiovascular and pacing implants, spinal repair and orthopedic procedures, and soft tissue reconstruction …

Merck

Cygnal Therapeutics nabs Merck, Takeda vet Wagner for CMO | FierceBiotech | 9/16/2020

… Foresite Capital, where he was a venture partner, bringing experience in early development and translational medicine from his time at Merck and Takeda. Over his career, Wagner has brought more than 150 prospects into human … including metabolic diseases, neurology, fibrosis, autoimmune disease, wound healing and regenerative medicine. “John brings a tremendous amount of experience in developing drugs and ushering therapeutics to market, and his extensive knowledge across multiple disease areas …

Boston Scientific

Regenerative tissue developer Aziyo Biologics files for $58M IPO | FierceBiotech | 9/16/2020

Regenerative medicine company Aziyo Biologics has filed for a $57.5 million Nasdaq IPO, with plans to expand its marketing and clinical development programs. With a focus on tissue-based products for patients receiving medical device implants, the company has previously partnered up with Medtronic, Boston Scientific, Biotronik and more—with its core, FDA-cleared offerings centered around cardiovascular and pacing implants, spinal repair and orthopedic procedures, and soft tissue reconstruction …

BrainStorm Cell Therapeutics

Brainstorm Announces Grant of a New Japanese Patent for NurOwn® | PR Newswire | 9/16/2020

NEW YORK , Sept. 16, 2020 /PRNewswire/ – Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japanese Patent Office (JPO) has granted Brainstorm’s Japanese … U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. Brainstorm …

Bristol-Myers

Vizgen Taps Akoya Biosciences Executive Terry Lo As New President and CEO | PR Newswire | 9/14/2020

… Manager, Quantitative Pathology Solutions. Previously, he held several executive positions at global biopharma and diagnostic companies including Roche, Hologic, and Bristol-Myers Squibb, and has extensive experience in launching innovative technologies in new markets. He … medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. For more information, go to www.vizgen.com , connect on social media @Twitter , @LinkedIn and Facebook , and join the MERFISH Group at: https://bit.ly/merfishgroup …

Bristol-Myers Squibb

Vizgen Taps Akoya Biosciences Executive Terry Lo As New President and CEO | PR Newswire | 9/14/2020

… Manager, Quantitative Pathology Solutions. Previously, he held several executive positions at global biopharma and diagnostic companies including Roche, Hologic, and Bristol-Myers Squibb, and has extensive experience in launching innovative technologies in new markets. He … medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. For more information, go to www.vizgen.com , connect on social media @Twitter , @LinkedIn and Facebook , and join the MERFISH Group at: https://bit.ly/merfishgroup …

Allergan

Targazyme Appoints Jim Caggiano as CEO | PR Newswire | 9/11/2020

… Caggiano brings nearly 30 years of immuno-oncology, pharmaceutical, and medical device experience at successful companies such as TAP Pharmaceuticals, Allergan, Abbott Laboratories, Valeant, and Dendreon. As President at Valeant, Caggiano led the successful business … also has promising programs in autoimmune diseases, gene therapy, and regenerative medicine. The Company’s clinical-grade fucosyltransferase enzymes and small molecule products (TZ-101 and TZ-102) are off-the-shelf products used during the …

Abbott Laboratories

Targazyme Appoints Jim Caggiano as CEO | PR Newswire | 9/11/2020

… brings nearly 30 years of immuno-oncology, pharmaceutical, and medical device experience at successful companies such as TAP Pharmaceuticals, Allergan, Abbott Laboratories, Valeant, and Dendreon. As President at Valeant, Caggiano led the successful business turnaround … also has promising programs in autoimmune diseases, gene therapy, and regenerative medicine. The Company’s clinical-grade fucosyltransferase enzymes and small molecule products (TZ-101 and TZ-102) are off-the-shelf products used during the …

Athersys

Global Stem Cells Industry | Globe Newswire | 9/9/2020

… term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, apceth Biopharma GmbH Athersys Inc. AVIVA BioSciences Corporation BioE Inc. Bone Therapeutics SA Cesca Therapeutics Inc. Cryo-Cell … by Region/Country in Percentage: 2020 VS 2027 Table 7: Regenerative Medicine (Application) Global Market Estimates & Forecasts in US$ Million by Region/Country: 2020-2027 Table 8: Regenerative Medicine (Application) Market Share Breakdown by Region/Country …

Amgen

Visiongain publishes Global Biosimilars and Follow-On Biologics Market 2020-2030 report | PR Newswire | 8/26/2020

… South Africa • Australia • Our study discusses the leading companies that are involved in the biosimilars and follow-on biologics industry: • Amgen Inc • Biocon Limited • Celltrion Healthcare Co. Ltd • Dong-A Socio Holdings Co. Ltd • Dr.Reddy’s … and Market Forecast to 2029 Global Bioreactors Market 2020-2030 Translational Regenerative Medicine Market Forecast 2020-2030 Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030 SOURCE Visiongain …

Thermo Fisher

Global 3D Cell Cultures Market 2020-2025 - COVID-19, Best Practices, Standardization, Regulations, Companies | Globe Newswire | 8/20/2020

… regenerative medicine, and xenotransplants Relevant patent analysis, including recent activity and a list of key patents Market share analysis of the major players in the industry and their comprehensive company profiles including Agilent Technologies, BioVision Inc., Cell Applications Inc., Envisiontec Inc., Mitra Biotech Inc., Promega Corp., and Thermo Fisher Scientific Whether the discussion is about stem cells, tissue engineering, or microphysiological systems, their vital role in drug discovery, toxicology, and …

Thermo Fisher Scientific

Global 3D Cell Cultures Market 2020-2025 - COVID-19, Best Practices, Standardization, Regulations, Companies | Globe Newswire | 8/20/2020

… regenerative medicine, and xenotransplants Relevant patent analysis, including recent activity and a list of key patents Market share analysis of the major players in the industry and their comprehensive company profiles including Agilent Technologies, BioVision Inc., Cell Applications Inc., Envisiontec Inc., Mitra Biotech Inc., Promega Corp., and Thermo Fisher Scientific Whether the discussion is about stem cells, tissue engineering, or microphysiological systems, their vital role in drug discovery, toxicology, and …

Integra LifeSciences

Regenerative Medicine Market to Grow at a CAGR of 26.1% to Reach USD 151,949.5 Billion by 2026 | Global Market Size, Trends, Growth, Analysis, Forecast Report [2019-2026] | Globe Newswire | 8/19/2020

Key Companies Covered in the Regenerative Medicine Market Report Are Integra LifeSciences Corporation, CELGENE CORPORATION, Medtronic, American CryoStem Corporation, Tissue Regenix, Avita Medical, Osiris Therapeutics, Inc., Wright Medical Group N.V., Smith & Nephew, Integra LifeSciences Corporation and other key market players. August 19, 2020 07:04 ET Source: Fortune Business Insights Pune, The regenerative medicine market size is expected to reach USD 151,949.5 billion by 2026, exhibiting a CAGR of 26.1% during …

Wright Medical

Regenerative Medicine Market to Grow at a CAGR of 26.1% to Reach USD 151,949.5 Billion by 2026 | Global Market Size, Trends, Growth, Analysis, Forecast Report [2019-2026] | Globe Newswire | 8/19/2020

Key Companies Covered in the Regenerative Medicine Market Report Are Integra LifeSciences Corporation, CELGENE CORPORATION, Medtronic, American CryoStem Corporation, Tissue Regenix, Avita Medical, Osiris Therapeutics, Inc., Wright Medical Group N.V., Smith & Nephew, Integra LifeSciences Corporation and other key market players. August 19, 2020 07:04 ET Source: Fortune Business Insights Pune, The regenerative medicine market size is expected to reach USD 151,949.5 billion by 2026, exhibiting a CAGR of 26.1% during …

Bluebird Bio

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 8/17/2020

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug 17, 2020– bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients … Food and Drug Administration (FDA) granted Orphan Drug status and Regenerative Medicine Advanced Therapy (RMAT) designation and rare pediatric disease designation for LentiGlobin for the treatment of SCD. bluebird bio reached general agreement with the …

Fate Therapeutics

Opportunities in the Global Induced Pluripotent Stem Cell (iPS Cell) Industry | PR Newswire | 8/11/2020

… allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its off-the-shelf iPSC-derived CAR-T cell product … significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials …

Adaptimmune

Adaptimmune Reports Q2 Financial Results and Business Update Nasdaq:ADAP | Globe Newswire | 8/6/2020

… into 2022 - - Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) - PHILADELPHIA and OXFORDSHIRE, United Kingdom, Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, today reported … ODD) in Europe, as well as the FDA’s ODD and Regenerative Medicine Advanced Therapy designation MANUFACTURING AND SUPPLY The Company has focused on manufacturing SPEAR T-cells for patients in the SPEARHEAD-1 trial and …

Gilead

Cryoport Reports 2020 Second-Quarter Results | PR Newswire | 8/6/2020

… from commercial therapies increased 38% over the prior year 26 net clinical trial adds, now supporting 491 clinical trials in Regenerative Medicine market News provided by Aug 06, 2020, 16:05 ET Share this article NASHVILLE … which was recently validated by the European Medicines Agency (“EMA”). “Gilead’s Kite renewed our agreement for temperature-controlled supply chain support of their commercial and clinical therapies, and we are in the final stages of …

Pfizer

Global Healthcare Nanotechnology (Nanomedicine) Industry Outlook 2020-2027 with Profiles of 46 Players Including Abbott Labs, Celgene Corp, GE Healthcare, J&J and Pfizer | PR Newswire | 8/5/2020

… Nanotechnology (Nanomedicine) Industry Outlook 2020-2027 with Profiles of 46 Players Including Abbott Labs, Celgene Corp, GE Healthcare, J&J and Pfizer News provided by Aug 05, 2020, 08:45 ET Share this article DUBLIN , Aug. 5 … the pandemic and its induced economic crisis, growth in the Regenerative medicine segment is readjusted to a revised 15.7% CAGR for the next 7-year period. The U.S. Market is Estimated at $54.3 Billion , While …

GE Healthcare

Global Healthcare Nanotechnology (Nanomedicine) Industry Outlook 2020-2027 with Profiles of 46 Players Including Abbott Labs, Celgene Corp, GE Healthcare, J&J and Pfizer | PR Newswire | 8/5/2020

Global Healthcare Nanotechnology (Nanomedicine) Industry Outlook 2020-2027 with Profiles of 46 Players Including Abbott Labs, Celgene Corp, GE Healthcare, J&J and Pfizer News provided by Aug 05, 2020, 08:45 ET Share this article DUBLIN … the pandemic and its induced economic crisis, growth in the Regenerative medicine segment is readjusted to a revised 15.7% CAGR for the next 7-year period. The U.S. Market is Estimated at $54.3 Billion , While …

Gilead Sciences

Novartis eyes 3rd Kymriah indication with follicular lymphoma trial win | FiercePharma | 8/5/2020

Novartis is hoping a third indication will help position Kymriah better against Gilead Sciences’ rival Yescarta in the CAR-T race—and it has positive early clinical results to back its case. Kymriah has hit … and the EU after that. The drug bears an FDA “regenerative medicine advanced therapy” designation, which could expedite its review process. However, Yescarta may be one step ahead of Kymriah in FL. At this year’s …

Versant Ventures

Graphite Bio Launches with $45 Million Series A Financing | Business Wire | 9/16/2020

… Calif.–(BUSINESS WIRE)–Sep 16, 2020– Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Graphite Bio is a next-generation gene editing company … Maria Grazia Roncarolo, M.D., Ph.D., Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine, Director of the Center for Definitive and Curative Medicine, and Co-Director of the Institute for Stem …

NCI

Notice of Correction to Eligibility in NIH Funding Opportunity Announcements | National Institutes of Health | 8/28/2020

… Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) PAR-20-278 - NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed) PAR-20-279 - Device-Based Treatments for … Center (SDCC) (U24 - Clinical Trial Not Allowed) RFA-HL-21-003 - Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 – Clinical Trial Required) RFA-MH-20-600 - BRAIN Initiative: Data Archives for the BRAIN Initiative …

RA Capital Management

Synthego Raises $100 Million to Accelerate CRISPR Platform Scale-up in Response to Growing Demand | PR Newswire | 8/26/2020

… announced that it raised $100 million in a Series D financing led by new investor Wellington Management, co-led by RA Capital Management and 8VC. Additional investors that participated included Founders Fund, Menlo Ventures, and … societies, including serving on multiple committees at the Alliance for Regenerative Medicine (ARM), and the International Society for Stem Cell Research (ISSCR). John Tan , M.B.A., joining Synthego as Chief Operating Officer, brings decades of global …

MPM Capital

ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference | Business & Finance | heraldchronicle.com | Business Wire | 8/25/2020

… company builders are creating a portfolio of therapeutics companies that are changing the face of cell and gene therapy and regenerative medicine. Core to ElevateBio’s vision is BaseCamp, a centralized state-of-the-art innovation … novel cell and gene therapies. ElevateBio’s investors include F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital, The Invus Group, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures HC. ElevateBio is headquartered in …

Redmile Group

ElevateBio to Present at the Morgan Stanley 18th Annual Global Healthcare Conference | Business & Finance | heraldchronicle.com | Business Wire | 8/25/2020

… company builders are creating a portfolio of therapeutics companies that are changing the face of cell and gene therapy and regenerative medicine. Core to ElevateBio’s vision is BaseCamp, a centralized state-of-the-art innovation … therapies. ElevateBio’s investors include F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital, The Invus Group, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures HC. ElevateBio is headquartered in Cambridge, Mass, with ElevateBio …

Smith & Nephew

Regenerative Medicine Market to Grow at a CAGR of 26.1% to Reach USD 151,949.5 Billion by 2026 | Global Market Size, Trends, Growth, Analysis, Forecast Report [2019-2026] | Globe Newswire | 8/19/2020

Key Companies Covered in the Regenerative Medicine Market Report Are Integra LifeSciences Corporation, CELGENE CORPORATION, Medtronic, American CryoStem Corporation, Tissue Regenix, Avita Medical, Osiris Therapeutics, Inc., Wright Medical Group N.V., Smith & Nephew, Integra LifeSciences Corporation and other key market players. August 19, 2020 07:04 ET Source: Fortune Business Insights Pune, The regenerative medicine market size is expected to reach USD 151,949.5 billion by 2026, exhibiting a CAGR of 26.1% during …

Morgan Stanley

Former Yahoo! Chairman, Wall Street Titan Roy J. Bostock Joins GID BIO as Chairman | PR Newswire | 7/28/2020

… LOUISVILLE, Colo. , July 28, Roy J. Bostock, former Chairman of Yahoo!, Vice Chairman of Delta Airlines and a director of Morgan Stanley, has joined the cellular medicine startup GID BIO that has a potentially break … BIO team is on the cusp of a breakthrough in regenerative medicine to treat significant diseases where there is no current solution. Cellular therapy could transform millions of lives and also reduce the staggering costs …

Alexandria Venture

Frequency Therapeutics Announces $42 Million Private Placement | Business Wire | 7/18/2020

… placement included Wasatch Global, Federated Hermes Kaufmann Funds, RTW Investments, Perceptive Advisors, Driehaus Capital Management, Maven Investment Partners US and Alexandria Venture Investments, in addition to other new and existing investors. The transaction is expected … millions of individuals suffering from hearing loss, and apply our regenerative medicine platform to other serious degenerative diseases including our remyelination work in multiple sclerosis,” said David L. Lucchino, Chief Executive Officer of Frequency Therapeutics …

Alexandria Venture Investments

Frequency Therapeutics Announces $42 Million Private Placement | Business Wire | 7/18/2020

… placement included Wasatch Global, Federated Hermes Kaufmann Funds, RTW Investments, Perceptive Advisors, Driehaus Capital Management, Maven Investment Partners US and Alexandria Venture Investments, in addition to other new and existing investors. The transaction is expected … millions of individuals suffering from hearing loss, and apply our regenerative medicine platform to other serious degenerative diseases including our remyelination work in multiple sclerosis,” said David L. Lucchino, Chief Executive Officer of Frequency Therapeutics …

Deerfield Management

Gene editing turns immune cells into more potent cancer killers | FierceBiotech | 6/15/2020

… by cytokines such as IL-15, said senior author Dan Kaufman, M.D., Ph.D., professor of medicine in the Division of Regenerative Medicine at the University of California, San Diego (UCSD), in a statement . The researchers … raised $114 million from the likes of Amgen Ventures and Deerfield Management to advance its pipeline of off-the-shelf NK cell therapies. Its lead candidate, NKX101, targets the cell surface receptor NKG2D and will …

Amgen Ventures

Gene editing turns immune cells into more potent cancer killers | FierceBiotech | 6/15/2020

… by cytokines such as IL-15, said senior author Dan Kaufman, M.D., Ph.D., professor of medicine in the Division of Regenerative Medicine at the University of California, San Diego (UCSD), in a statement . The researchers … Last September, Nkarta raised $114 million from the likes of Amgen Ventures and Deerfield Management to advance its pipeline of off-the-shelf NK cell therapies. Its lead candidate, NKX101, targets the cell surface receptor …

Bruker

$5.9 Billion Failure Analysis Market Outlook, 2025 - Implications of COVID-19, Trends & Developments, Key Players | PR Newswire | 5/28/2020

… in demand for failure analysis from the electronics & semiconductor industry, technological advancements in microscopes, and rising focus on nanotechnology and regenerative medicine. Energy Dispersive X-Ray Spectroscopy (EDX) technology expected to hold the largest share … Zeiss ( Germany ), JOEL, Ltd. ( Japan ), TESCAN OSRAY HOLDING ( Czech Republic ), Bruker (US), Semilab ( Hungary ), A&D Company, Ltd. ( Japan ), HORIBA, Ltd. ( Japan ), Leica Microsystems GmbH ( Germany ), Veeco Instruments (US), Oxford Instruments (UK), and Eurofins Scientific …

TPG Capital

ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes | PR Newswire | 5/26/2020

SAN DIEGO ViaCyte, Inc. , a privately held regenerative medicine company, today announced the close of an approximately $27 million private financing, part of the Series D preferred stock financing entered into in late 2018. Investors included, Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further advance the Company’s multi-product candidate approach …

Goldman Sachs

CRISPR Therapeutics to Participate in Upcoming Investor Conferences | Globe Newswire | 5/26/2020

… in the following investor conferences in June: Jefferies Global Healthcare Conference Date: Tuesday, June 2, 2020Fireside chat: 1:30 p.m. ET Goldman Sachs 41st Annual Global Healthcare Conference Date: Tuesday, June 9, 2020 Fireside chat: 9:40 … across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and …

Stryker

Tissue Engineering Market Size Worth $28.9 Billion by 2027 | CAGR: 14.2%: Grand View Research, Inc. | PR Newswire | 5/25/2020

… the Asia Pacific region throughout the forecast period Medtronic plc; Zimmer Biomet Holdings, Inc; Allergan plc; Athersys, Inc; ACell, Inc.; Stryker Corporation; Integra LifeSciences Corporation; and Baxter International, Inc. are the key players operating in … and-regeneration-industry Rapid advancements and a strong pipeline of regenerative medicine are anticipated to provide effective solutions for chronic conditions. Several companies in growing markets are striving to capitalize on the untapped market potential …

Daiichi Sankyo

Asia-Pacific CAR-T Pipeline Insights 2020 Featuring Over 50 CAR-T Therapy Companies in the Region | Globe Newswire | 5/15/2020

… Pacific CAR-T Pipeline” report has been added to ResearchAndMarkets.com’s offering. The Asia-Pacific CAR-T pipeline features over 50 regenerative medicine companies focusing on CAR-T in Asia. The report derives insights from in … Nanjing Legend Biotech, CARsgen Therapeutics, JW Therapeutics, AbClon, BiocurePharm, Eutilex, Daiichi Sankyo, Celgene, Otsuka and many more. Key Topics Covered …

Needham & Company

Athersys Announces Closing of Public Offering of Common Stock | Yahoo News | 4/20/2020

… before deducting the underwriting discount and estimated offering expenses. BofA Securities acted as sole book-running manager for the offering. Needham & Company, SMBC and WBB Securities acted as co-managers for the offering. Athersys intends … indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. Forward-Looking …

Wellcome Trust

Orbsen Therapeutics Launches Clinical Trial to Address Leading Cause of Death Among COVID-19 Patients | PRWeb | 4/8/2020

… to the arsenal of therapies to combat the effects of COVID-19.” The phase 2a clinical trial, funded by the Wellcome Trust, has been approved by the United Kingdom’s Medical Health Regulatory Agency (MHRA). Also … of cellular immunotherapy. The company, which spun-out from Ireland’s Regenerative Medicine Institute at the National University of Ireland Galway, has developed proprietary technologies that enables the isolation of a well characterized population of pure …

Section 32

Vineti Completes $35 Million in Series C Financing to Industrialize Personalized and High-Value Therapeutics | Globe Newswire | 2/5/2020

… and Kite, a Gilead Company (Gilead Sciences, Inc.), as well as existing Vineti investors – Canaan Partners, Threshold Ventures (formerly DFJ), Section 32, LifeForce Capital, Casdin Capital, and Hive Ventures, along with other undisclosed entities. A … could enroll almost 60,000 patients , according to the Alliance for Regenerative Medicine. “Those of us with experience in personalized therapeutics understand that innovative technology is required to support breakthrough science,” said Joe DePinto, President of …

Flagship Pioneering

Cygnal Therapeutics Announces Scientific Advisory Board | PR Newswire | 1/31/2020

… Dr. Frenette has served as the director of the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research at the Albert Einstein College of Medicine, Montefiore Health System in New … the company’s website at www.cygnaltx.com . About Cygnal Therapeutics Founded by Flagship Pioneering in 2017, Cygnal Therapeutics is the first company to build a platform to develop drugs in the new field of exoneural biology, an …

EW Healthcare Partners

Cognate BioServices closes Series B and completes acquisition of Cobra Biologics | PR Newswire | 1/22/2020

… Biologics, a leading CDMO specialized in providing development and manufacturing services for plasmid DNA and viral vector. Existing Cognate shareholder, EW Healthcare Partners and its co-investors led the investment in Cognate and the financing … and manufacturing solutions to the cell and gene immunotherapy and regenerative medicine industry around the world. Cobra Biologics has cGMP facilities in the UK and Sweden. Cognate operates an 80,000+ square foot manufacturing facility located …

Zacks Equity Research

3D Systems Joins CollPlant in Regenerative Medicine Efforts | Zacks | 1/14/2020

3D Systems Joins CollPlant in Regenerative Medicine Efforts Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article 3D Systems ( DDD - Free Report ) recently partnered with CollPlant Biotechnologies ( CLGN - Free Report ) to jointly develop tissue and scaffold bioprinting processes for third party companies, aiming to expedite the advancements in the biomedical …

Merrill Lynch

H.C. Wainwright Strengthens Its M&A and Advisory Capabilities | Business Wire | 1/13/2020

… a focus in healthcare and the life sciences, having worked in research and investment banking at Hambrecht & Quist, Cowen & Company, Merrill Lynch & Co. and T.R. Winston & Company. In addition, Mr. Meyers has served as a … T.R. Winston & Company. Mr. Jakimo is a Director of the Regenerative Medicine Foundation and The Cancer Trust, both not-for-profit organizations. He also serves on corporate advisory boards at the Columbia University Center for …

Domain Associates

Aspen Neuroscience Announces Board of Directors and Scientific Advisory Board | PR Newswire | 1/9/2020

… will help guide the company’s progress toward regulatory approval,” said Kim P. Kamdar , PhD, Aspen Board Chair and Partner at Domain Associates. “The members of each board bring significant expertise, complementary skills and an external … Advisory Board consists of leaders in the fields of bioethics, regenerative medicine clinical trials, autologous iPSC-based therapy, and Parkinson disease neuron replacement and neuroimaging. Aspen Neuroscience Scientific Advisory Board Roger Barker , MBBS, MRCP, PhD …

Innovation Fund

Promethera Attracts Sony Innovation Fund by IGV and Pegasus Tech Ventures as New Investors in Final Closing of Series D | PR Newswire | 12/16/2019

… today announced the addition of €7.5 million to its recent €39.7 million Series D financing led by new investors Sony Innovation Fund by IGV and Pegasus Tech Ventures. MEDIPAL Holdings, the family office Six Snow … the leading drug development organization in cell-based therapies and regenerative medicines targeting severe liver disorders.” Mr. Gen Tsuchikawa, CEO at Innovation Growth Ventures (IGV) added, “We decided to invest in Promethera due to the …

Sanford Health

FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) | PR Newswire | 9/16/2020

NEW YORK , Sept. 16, The Cura Foundation in collaboration with The Marcus Foundation, Sanford Health and Alliance for Cell Therapy Now, is supporting a clinical trial of human cord tissue mesenchymal stromal cells (hCT-MSC … Duke Health and a leader in transplantation, cell therapy, and regenerative medicine in children. Clinical sites include Duke University ( Durham, NC ), Children’s Healthcare of Atlanta ( Atlanta, GA ), New York Medical College ( Valhalla, NY ), and others …

Brigham and Women's Hospital

Vizgen Taps Akoya Biosciences Executive Terry Lo As New President and CEO | PR Newswire | 9/14/2020

… Dr. David R. Walt , Cofounder of Vizgen; Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School ; Professor of Pathology, Brigham and Women’s Hospital; Core Faculty, Wyss Institute for Bioinspired Engineering, Harvard University ; HHMI Professor … medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. For more information, go to www.vizgen.com , connect on social media @Twitter , @LinkedIn and Facebook , and join the MERFISH Group at: https://bit.ly/merfishgroup …

Harvard Medical School

Vizgen Taps Akoya Biosciences Executive Terry Lo As New President and CEO | PR Newswire | 9/14/2020

… President and CEO of Vizgen,” said Dr. David R. Walt , Cofounder of Vizgen; Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School ; Professor of Pathology, Brigham and Women’s Hospital; Core Faculty, Wyss Institute for … medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. For more information, go to www.vizgen.com , connect on social media @Twitter , @LinkedIn and Facebook , and join the MERFISH Group at: https://bit.ly/merfishgroup …

Hackensack University Medical Center, Hackensack NJ

Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patients | PR Newswire | 9/8/2020

Regenerative Medicine (CIRM). Participating trial sites include Hackensack University Medical Center and Atlantic Health in New Jersey , MultiCare Health System in Washington State , Banner University Medical Center Phoenix in Arizona , the University of Arkansas in Arkansas , and UC Davis in California . The Principal Investigator is Corey Casper , M.D., MPH, of the Infectious Disease Research Institute (IDRI) ClinicalTrials.gov Identifier: NCT04365101 . “Through this collaboration with our partner sites, we were able to …

University of Pittsburgh Medical Center

LyGenesis Announces Four Peer-Reviewed Publications on its Organ Regeneration Technology | PR Newswire | 8/27/2020

PITTSBURGH , Aug. 27, LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis’ lead development asset is liver regeneration, which … of the Liver Transplant Program, Starzl Transplant Institute at the University of Pittsburgh Medical Center. “Showing that our cellular therapy was able to safely and effectively induce organogenesis – the forming of a novel, well-vascularized …

Mayo Clinic

Continuing importance of stem cell research: Expanding medical knowledge | LA Times | 8/25/2020

… research could benefit the world by providing breakthroughs in addressing the needs for replacement organs and tissues. According to the Mayo Clinic, stem cells mature into cells “in bones, heart muscle, nerves and other organs … leading to restored vision for the nearly blind test subjects. Regenerative medicine holds great promise for people suffering from eye disease. This successful stem cell trial reinforces the importance of stem cell research in all …

St. Jude Children's Research Hospital

Dr. Tanja Gruber named director of Stanford Children’s center for childhood cancer, blood diseases | Becker’s Hospital Review | 8/21/2020

regenerative medicine at the Stanford (Calif.) University School of Medicine and associate director for childhood cancer at the Stanford Cancer Institute. Most recently, Dr. Gruber served as an associate member of the molecular oncology division at Memphis, Tenn.-based St. Jude Children’s Research Hospital, where she also ran a research laboratory and national clinical trials. Dr. Gruber completed her residency and fellowship in hematology and oncology at Children’s Hospital Los …

Stanford Medicine

Stanford Children’s Health Appoints New Chief of Pediatric Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine | PR Newswire | 8/20/2020

… PRNewswire/ – Physician-scientist Tanja Gruber , MD, PhD, has been appointed Division Chief of Hematology, Oncology , and Stem Cell Transplantation and Regenerative Medicine in the Division of Pediatrics at the Stanford University School of Medicine , Associate … 85 locations in the U.S. Western region. As part of Stanford Medicine , a leading academic health system that also includes Stanford Health Care and Stanford University School of Medicine, we are cultivating the next generation …

Memorial Sloan Kettering Cancer Center

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 8/17/2020

… cerebral disease status (ALD-103) Presenting Author: Dr. Jaap Jan Boelens, Chief, Pediatric Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center Poster Session & Number: Haemoglobinopathy and inborn errors; ePoster O106 Multiple … Food and Drug Administration (FDA) granted Orphan Drug status and Regenerative Medicine Advanced Therapy (RMAT) designation and rare pediatric disease designation for LentiGlobin for the treatment of SCD. bluebird bio reached general agreement with the …

Memorial Sloan Kettering

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 8/17/2020

… cerebral disease status (ALD-103) Presenting Author: Dr. Jaap Jan Boelens, Chief, Pediatric Stem Cell Transplantation and Cellular Therapies Service, Memorial Sloan Kettering Cancer Center Poster Session & Number: Haemoglobinopathy and inborn errors; ePoster O106 Multiple … Food and Drug Administration (FDA) granted Orphan Drug status and Regenerative Medicine Advanced Therapy (RMAT) designation and rare pediatric disease designation for LentiGlobin for the treatment of SCD. bluebird bio reached general agreement with the …

Columbia University Medical Center

bluebird bio to Present New Data from Clinical Studies of elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the Virtual Edition of the 46th EBMT Annual Meeting | Business & Finance | heraldchronicle.com | Business Wire | 8/17/2020

… from the Phase 1/2 HGB-206 study Presenting Author: Dr. Markus Y. Mapara, Director, Adult Blood and Marrow Transplantation Program, Columbia University Medical Center Oral Session & Number: Inborn Errors; O080 Date & Time: September 1, 2020 … Food and Drug Administration (FDA) granted Orphan Drug status and Regenerative Medicine Advanced Therapy (RMAT) designation and rare pediatric disease designation for LentiGlobin for the treatment of SCD. bluebird bio reached general agreement with the …

Massachusetts General Hospital

ViaCyte Appoints Dr. Manasi Sinha Jaiman as Vice President, Clinical Development | PR Newswire | 8/13/2020

SAN DIEGO , Aug. 13, ViaCyte, Inc. , a clinical stage regenerative medicine company, today announced the appointment of Manasi Sinha Jaiman , M.D., M.P.H. as Vice President, Clinical Development. Dr. Jaiman joins ViaCyte from Covance Clinical Development Services, where she was Senior Medical Director. She was also an attending physician at Harvard Medical School and Massachusetts General Hospital, where she was responsible for clinical care of type 1 and type 2 diabetes …

Medical University of South Carolina

ViaCyte Appoints Dr. Manasi Sinha Jaiman as Vice President, Clinical Development | PR Newswire | 8/13/2020

SAN DIEGO , Aug. 13, ViaCyte, Inc. , a clinical stage regenerative medicine company, today announced the appointment of Manasi Sinha Jaiman , M.D., M.P.H. as Vice President, Clinical Development. Dr. Jaiman joins ViaCyte from Covance Clinical Development … how diabetes is treated.” Dr. Jaiman received her M.D. from Medical University of South Carolina and M.P.H. from Tulane University School of Public Health and Tropical Medicine . She completed her pediatric residency at Dartmouth-Hitchcock …

MD Anderson Cancer Center

Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma | Business Wire | 7/27/2020

… medical need in treating patients with MCL by Michael Wang, MD, professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center. Dr. Wang, a consultant to Oncternal, will be available to answer … San Diego School of Medicine and the California Institute for Regenerative Medicine (CIRM). In addition, an investigator-initiated Phase 1 clinical trial of cirmtuzumab in combination with paclitaxel for women with HER2-negative metastatic breast …

University of Texas MD Anderson Cancer Center

Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma | Business Wire | 7/27/2020

… landscape and unmet medical need in treating patients with MCL by Michael Wang, MD, professor of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center. Dr. Wang, a consultant to Oncternal, will be … San Diego School of Medicine and the California Institute for Regenerative Medicine (CIRM). In addition, an investigator-initiated Phase 1 clinical trial of cirmtuzumab in combination with paclitaxel for women with HER2-negative metastatic breast …

Penn Medicine

‘Self-eating’ process of stem cells may be the key to new regenerative therapies | Phys Org | 7/23/2020

… CMA) and a related metabolite may serve as promising new therapeutic targets to repair or regenerate damaged cells and organs, Penn Medicine researchers show in a new study published online in Science . Human bodies contain … could be a powerful way to increase the efficiency of regenerative medicine approaches.” Autophagy is a cell-eating mechanism necessary for survival and function of most living organisms. When cells self-eat, the intracellular materials …

Baylor College of Medicine

Global Cart Cell Therapy Market To Grow At A CAGR of 29.4% With The Emergence Of Immunotherapies In Medical Treatment | Globe Newswire | 7/22/2020

… 2, the virus causing the current pandemic. Several organizations are also working on cell therapies for COVID-19. AlloVir and Baylor College of Medicine have partnered to develop an off-the-shelf therapy to target … Leukemia, and Others) – Market Forecast & Assessment (2017-2028). ” Browse Related Reports Regenerative Medicine Market , By Type (Cell-Based Immunotherapy & Cell Therapy Products, Tissue-Engineered Products, Gene Therapy Products), Application (Wound Care, Musculoskeletal Disorders, Oncology, Ocular Disorders …

Cedars-Sinai Medical Center

BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS | PR Newswire | 7/2/2020

… later in 2020.” The Phase 3 NurOwn trial is being conducted at six centers of excellence: University of California, Irvine ; Cedars-Sinai Medical Center ; California Pacific Medical Center ; Massachusetts General Hospital ; University of Massachusetts Medical … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

California Pacific Medical Center

BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS | PR Newswire | 7/2/2020

… Phase 3 NurOwn trial is being conducted at six centers of excellence: University of California, Irvine ; Cedars-Sinai Medical Center ; California Pacific Medical Center ; Massachusetts General Hospital ; University of Massachusetts Medical School and Mayo Clinic … sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm …

Boston University School of Medicine

Differentiation of Human Airway-Organoids From Induced Pluripotent Stem Cells (iPSCs) - PubMed | National Institutes of Health | 6/28/2020

Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, United States; Division of Respiratory Diseases, Department of Medicine, Boston Children’s Hospital, Boston, MA, United States. 2 Respiratory Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA, United States. 3 Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, United States; Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA, United States …

Boston Medical Center

Differentiation of Human Airway-Organoids From Induced Pluripotent Stem Cells (iPSCs) - PubMed | National Institutes of Health | 6/28/2020

doi: 10.1016/bs.mcb.2020.03.008. Epub 2020 Apr 25. Authors Ruobing Wang 1 , Katie B McCauley 2 , Darrell N Kotton 3 , Finn Hawkins 4 Affiliations 1 Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, United States; Division of Respiratory Diseases, Department of Medicine, Boston Children’s Hospital, Boston, MA, United States. 2 Respiratory Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA, United States. 3 Center for Regenerative …

Boston Medical Center, Boston MA

Differentiation of Human Airway-Organoids From Induced Pluripotent Stem Cells (iPSCs) - PubMed | National Institutes of Health | 6/28/2020

doi: 10.1016/bs.mcb.2020.03.008. Epub 2020 Apr 25. Authors Ruobing Wang 1 , Katie B McCauley 2 , Darrell N Kotton 3 , Finn Hawkins 4 Affiliations 1 Center for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, United States; Division of Respiratory Diseases, Department of Medicine, Boston Children’s Hospital, Boston, MA, United States. 2 Respiratory Diseases, Novartis Institutes for BioMedical Research, Cambridge, MA, United States. 3 Center for Regenerative …

Mayo Clinic Health System

Mayo Clinic launches innovation exchange | Becker’s Hospital Review | 6/25/2020

… include virtual office hours with law firms as well as marketing and strategy consultants.Members will also receive targeted introductions to Mayo Clinic Health System experts. The exchange is currently taking applications.The health system also has … Ventures and director of business development in the Center for Regenerative Medicine at Mayo Clinic in Florida. Dr. Bruce has helped create five start-up companies and is a patent inventor on more than 160 …

Kaiser Permanente

Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy | Globe Newswire | 6/17/2020

… chip investors also participated in the latest round, including 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust and IMRF. The financing will support the continued advancement of Orca … Director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine at Stanford University Ted Love, MD, Global Blood Therapeutics (GBT) Jonathan MacQuitty, PhD, Venture Partner at Lightspeed Venture Partners Joe Jimenez, Former Chief …

Indiana University School of Medicine

Fact check: Early research shows fabric could neutralize coronaviruses | Yahoo News | 5/30/2020

Regenerative Medicine and Engineering at the Indiana University School of Medicine. While working at Ohio State University in 2017, he created an electrically based antimicrobial wound dressing that has been approved by the FDA and sold by Vomaris under the name Procella. Sen detailed the potential application to COVID-19 on May 14 in a preliminary study released online at the preprint server ChemRxiv. The site publishes early versions of …

Health Net

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results Nasdaq:CRSP | Globe Newswire | 7/27/2020

Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease (SCD)- -Expands regenerative medicine portfolio through a collaboration with University Health Network (UHN), gaining access to hepatocytes- ZUG, Switzerland and CAMBRIDGE, Mass., CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results …

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results | Globe Newswire | 7/27/2020

July 27, 2020 16:30 ET Source: CRISPR Therapeutics AG -Dosing re-initiated in clinical trials of CTX001™ for patients with severe hemoglobinopathies- - CTX001 has received orphan drug designation from the U.S. FDA for sickle cell disease (SCD)- -Expands regenerative medicine portfolio through a collaboration with University Health Network (UHN), gaining access to hepatocytes- ZUG, Switzerland and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company …

Healthspan

Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development | Benzinga | 9/24/2019

HOUSTON , Sept. 24, 2019 /PRNewswire/ – Houston Healthspan Innovation Group is a new accelerator for early stage life sciences and biotech companies focused on the research, development and commercialization of new therapies and technologies in the expanding field of regenerative medicine. The brainchild of CEO and Founder Dr. Ed Bosarge , a pioneer in advancing leading-edge life sciences projects, Houston Healthspan will offer start-up companies and joint-venture partners access …

Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development | 9/24/2019

HOUSTON , Sept. 24, 2019 /PRNewswire/ – Houston Healthspan Innovation Group is a new accelerator for early stage life sciences and biotech companies focused on the research, development and commercialization of new therapies and technologies in the expanding field of regenerative medicine

Yehiel Tal

CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant | PR Newswire | 9/21/2020

… English Expanded collaboration combines CollPlant’s proprietary BioInk that is based on its recombinant human collagen (rhCollagen) technology and United Therapeutics’ regenerative medicine and organ manufacturing capabilities Collaboration aims to help reduce global organ shortages of … made significant progress with this pivotal organ manufacturing initiative,” stated Yehiel Tal , the Chief Executive Officer of CollPlant. “United Therapeutics is pioneering the emerging organ manufacturing field, and we are honored to be part of …

Chaim Lebovits

Brainstorm Announces Grant of a New Japanese Patent for NurOwn® | PR Newswire | 9/16/2020

… to our IP portfolio for the NurOwn® technology and is an important element of our business strategy” commented Brainstorm’s CEO Chaim Lebovits. David Setboun, PharmD MBA, EVP and Chief Operating Officer, added: “Having our cell … U.S., supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. Brainstorm …

Robin Smith

FDA Approves Study to Investigate the Use of Cell Therapy to Treat COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C) | PR Newswire | 9/16/2020

regenerative medicine in children. Clinical sites include Duke University ( Durham, NC ), Children’s Healthcare of Atlanta ( Atlanta, GA ), New York Medical College ( Valhalla, NY ), and others as cases occur. “We hope this is just the beginning of our ability to support the development of cell therapies to treat COVID-19 Related Multisystem Inflammatory Syndrome in Children,” said Dr. Robin Smith, president of the Cura Foundation. “As students across the country return …

James L. Sherley

Asymmetrex Reports the First Quantitation of “True” Tissue Stem Cells In Stem Cell History | PRWeb | 9/15/2020

… therapies require true stem cells; and gene therapies must target true stem cells with their curative genetic engineering. Asymmetrex director, James L. Sherley, M.D., Ph.D., says, “So, it is no surprise that now being able … of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test …

Brian M. Culley

Lineage Cell Therapeutics Awarded Grant From Israel Innovation Authority for Development of a Bio-Retinal Patch for Treatment of Retinal Diseases in Partnership With Precise Bio | Business Wire | 9/8/2020

… is increasing our confidence in the use of cell transplants to treat serious retinal conditions such as dry AMD,” said Brian M. Culley, Lineage’s CEO. “OpRegen is a suspension of RPE cells, but in certain … notable institutions such as the IIA, the California Institute for Regenerative Medicine and Cancer Research UK , provide not only capital but external validation of our programs, and we are working to strengthen and expand these …

Ralph Kern

BrainStorm to Present at Scientific Conferences in September | Globe Newswire | 9/3/2020

WuXi Apptec- Collaborations That Transform Meeting (Multiple Sclerosis) Presenter: Ralph Kern, MD, MHSc, President and Chief Medical Officer Time: September 24, 2020 10:30 AM– 12:30 PM ET Webcast: Link will be posted on the Events … non-dilutive grant of $16 million by California Institute for Regenerative Medicine (CIRM) to support the ongoing Phase 3 study of NurOwn ® , for the treatment of amyotrophic lateral sclerosis (ALS). About BrainStorm Cell Therapeutics Inc …

Manuel Litchman

Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants | Globe Newswire | 9/2/2020

… newly diagnosed infants under the age of two. The FDA previously granted Rare Pediatric Disease Designation in August 2020 and Regenerative Medicine Advanced Therapy designation in August 2019 to MB-107 for the treatment of … of market exclusivity, which is independent from intellectual property protection. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “Mustang has had a productive quarter on the regulatory front. We are very pleased …

George Shapiro

Three New COVID-19 Patients Treated with Zofin™ Report Improvement | Business Wire | 9/2/2020

MIAMI- Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat … improvement in energy levels and her brain fog has disappeared. George Shapiro, M.D., Chief Medical Officer of Organicell said, “The six outpatients with different stages of COVID-19 were treated with Zofin under an emergency …

David Nichol

Orthobiologics Associates Selects AMP Recover For Virtual Care Delivery | PR Newswire | 8/24/2020

PRNewswire/ – Orthobiologics Associates, a leader in regenerative medicine technology, has implemented AMP Recover’s protocol management platform to deliver best in class rehabilitation experiences to their patients. Dr. Vincent DePasquale, D.C. Founder of Orthobiologics Associates and … niche of traditional orthopedics and sports medicine,” says AMP CEO David Nichols . “The AMP Recover framework is applicable in a lot of clinical use cases. Our tools unite caregivers and patients on a journey towards …

Alan Condon

$2.8M+ NIH grant awarded to Steadman Philippon Research Institute for stem cell research | Beckers Spine Review | 8/21/2020

2.8M+ NIH grant awarded to Steadman Philippon Research Institute for stem cell research Alan Condon - Print Email The Steadman Philippon Research Institute in Vail, Colo., has received a grant from the National Institutes of Health … Aug. 20 news release. The funding is part of NIH’s Regenerative Medicine Innovation Project, which aims to accelerate clinical research around adult stem cells. Johnny Huard, PhD, who joined SPRI as chief scientific officer in …

Johnny Huard

$2.8M+ NIH grant awarded to Steadman Philippon Research Institute for stem cell research | Beckers Spine Review | 8/21/2020

Regenerative Medicine Innovation Project, which aims to accelerate clinical research around adult stem cells. Johnny Huard, PhD, who joined SPRI as chief scientific officer in 2015, will act as principal investigator for the clinical trials. Marc J. Philippon, MD, managing partner of The Steadman Clinic and co-chair of SPRI, and Scott Tashman, PhD, director of biomedical engineering at SPRI, will serve as co-principal investigators. Enrollment for the clinical …

Peter Marks

How do you separate scientifically sound stem cell therapies from scams? | STAT | 8/18/2020

… unproven therapies like stem cell treatments offer new hope. But how do you sort the scientifically legitimate from the dangerous? Regenerative medicine is a controversial field, still in its infancy. There are academic researchers and … a top official at the Food and Drug Administration, said Peter Marks, who helms the agency’s biologics center. On a recent trip to Florida, he walked by a stem cell clinic offering unproven therapies. “I …

Steven Rose

Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research | Business Wire | 8/15/2020

Regenerative Medicine (NCRM), which honours scientists or clinicians whose contributions lead to the development of prevention, diagnosis or treatment of any disease, through an inter-disciplinary approach. Alumni of the Fujio Cup Quiz, a part of NCRM NICHE, ( www.ncrmniche.org ), have priority for nomination, a unique feature of this prize. Previous awardees include Prof James Till, University of Toronto, Canada for discovery of stem cells (2018) and Dr. Steven Rosenberg, National …

Steven Rosen

Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research | Business Wire | 8/15/2020

Regenerative Medicine (NCRM), which honours scientists or clinicians whose contributions lead to the development of prevention, diagnosis or treatment of any disease, through an inter-disciplinary approach. Alumni of the Fujio Cup Quiz, a part of NCRM NICHE, ( www.ncrmniche.org ), have priority for nomination, a unique feature of this prize. Previous awardees include Prof James Till, University of Toronto, Canada for discovery of stem cells (2018) and Dr. Steven Rosenberg, National …

Steven Rosenberg

Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research | Business Wire | 8/15/2020

Regenerative Medicine (NCRM), which honours scientists or clinicians whose contributions lead to the development of prevention, diagnosis or treatment of any disease, through an inter-disciplinary approach. Alumni of the Fujio Cup Quiz, a part of NCRM NICHE, ( www.ncrmniche.org ), have priority for nomination, a unique feature of this prize. Previous awardees include Prof James Till, University of Toronto, Canada for discovery of stem cells (2018) and Dr. Steven Rosenberg, National …

Greg Bailey

AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update | Business Wire | 8/14/2020

… a research license for the use of its immunotolerance UniverCyte TM technology by Sernova Corp. (“Sernova”), a publicly-listed Canadian regenerative medicine therapeutics company. It also entered a Manufacturing, Marketing, and Distribution Agreement with Pluristyx … deals since the beginning of the year so far,” said Greg Bailey M.D., Chairman of AgeX. “The deals have spanned all three of our technology platforms of UniverCyte for the generation of universal cells, PureStem …

Christopher C. Reeg

Fuse Medical, Inc. Ranked Among Top 150 Public Companies in Dallas-Fort Worth Metroplex | Business Wire | 8/14/2020

… in a seventy-county area in North Texas, and ranks them by their total revenue for the prior fiscal year. Christopher C. Reeg, Chief Executive Officer, commented, “We are honored to have been named by … space, as well as, degenerative and deformity spine, orthobiologics and regenerative medicine products. For more information about the Company, or if you’re interested in becoming a distributor of any Fuse’s products, please contact us at …

Michael West

AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update | Business Wire | 8/14/2020

… a research license for the use of its immunotolerance UniverCyte TM technology by Sernova Corp. (“Sernova”), a publicly-listed Canadian regenerative medicine therapeutics company. It also entered a Manufacturing, Marketing, and Distribution Agreement with Pluristyx … optimize the potential of induced tissue regeneration (iTR) technology,” said Michael West, CEO of AgeX. “We believe this technology offers a powerful new modality to treat age-related degenerative diseases by reversing developmental aging in …

Steven Romano

Mallinckrodt Announces U.S. FDA Filing Acceptance of Biologics License Application for StrataGraft® Regenerative Skin Tissue for Treatment of Adults with Deep Partial-thickness Thermal Burns | PR Newswire | 8/10/2020

… adult burn patients in the United States with a potential new treatment option for deep partial-thickness thermal burns,” said Steven Romano , M.D., Executive Vice President and Chief Scientific Officer at Mallinckrodt . “We are focused … among the first products designated by the Agency as a Regenerative Medicine Advanced Therapy (RMAT) under the provisions of the 21st Century Cures Act. About StrataGraft StrataGraft regenerative skin tissue is an investigational treatment being …

Shai Yarkoni

European Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation | PR Newswire | 8/6/2020

… IP protection over the second component of the Apograft ™ effects – the activation of the stem and progenitor cells,” commented Dr. Shai Yarkoni , Chief Executive Officer. “While the extensive issued patents cover the accurate elimination (negative … treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment. Forward Looking Statements This press release contains forward-looking …

Jerrell Shelton

Cryoport Reports 2020 Second-Quarter Results | PR Newswire | 8/6/2020

… from commercial therapies increased 38% over the prior year 26 net clinical trial adds, now supporting 491 clinical trials in Regenerative Medicine market News provided by Aug 06, 2020, 16:05 ET Share this article NASHVILLE … our clinical and commercial portfolios globally and without disruption,” said Jerrell Shelton , Chairman and Chief Executive Officer. “Our Second Quarter results reflect the strength and resilience of our company where we saw continued year-over …

Robert Harman

Personalized Stem Cells Announces Completion of Enrollment for FDA Approved Stem Cell Clinical Trial for Knee Arthritis | PR Newswire | 8/5/2020

… affected knee. This enrollment milestone is an important step forward in the completion of the clinical trial. PSC CEO, Dr. Robert Harman , stated, “We are fortunate to have a fully enrolled trial which will allow … Personalized Stem Cells was formed in 2018 to advance human regenerative medicine by securing FDA approval for serious diseases with limited treatment options. This privately held biopharmaceutical enterprise, based near San Diego ( California ), offers qualified …

Michael Dale

Personalized Stem Cells Announces Completion of Enrollment for FDA Approved Stem Cell Clinical Trial for Knee Arthritis | PR Newswire | 8/5/2020

… injury (concussion), as well as arthritis affecting other joints. PSC was founded in 2018 by Robert Harman , DVM, MPVM and Michael Dale , both of whom also co-founded VetStem Biopharma and are both experienced serial … Personalized Stem Cells was formed in 2018 to advance human regenerative medicine by securing FDA approval for serious diseases with limited treatment options. This privately held biopharmaceutical enterprise, based near San Diego ( California ), offers qualified …

John Tsai

Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma Swiss Stock Exchange:NOVN | Globe Newswire | 8/4/2020

… patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in r/r FL based on preliminary ELARA trial … option for patients with relapsed and refractory follicular lymphoma,” said John Tsai, MD, Head of Global Drug Development and Chief Medical Officer, Novartis. “These results further support our efforts to reimagine medicine in this incurable …

Margot Connor

The Washington Post Names RoosterBio a 2020 Top Washington-area Workplace | PRWeb | 7/30/2020

The Washington Post Names RoosterBio a 2020 Top Washington-area Workplace Share Article The third award received by the RoosterBio for its outstanding workplace culture since 2019 As our leadership team was transforming RoosterBio from an incubator startup company into a worldwide regenerative medicine products leader, we wanted to build the kind of company we all wanted to work for. - RoosterBio CEO Margot Connor FREDERICK, Md. (PRWEB) July 30, 2020 …

State of California

These 2 Penny Stocks Could See Outsized Gains, Says Oppenheimer | 10/13/2020

Column: The California stem cell program’s $5.5-billion funding request might be its downfall The California Institute for Regenerative Medicine is seeking a new $5.5-billion infusion. It must go back to the drawing board. The route to cures was always more complex than the campaign led on, and none has yet emerged for those headline maladies. Meanwhile, CIRM has come almost to the end of its original $3-billion …

Denver, Colorado

Get The Best Chronic Pain Management Regenerative Medicine Solutions In Denver | 9/29/2020

PR Agency - Tuesday, September 29, 2020. If you’re looking for an effective non-surgical treatment for chronic pain, the team at Aspen Institute for Anti-Aging & Regenerative Medicine has the solution for you! Aspen Institute for Anti-Aging & Regenerative Medicine announced the launch of an updated range of stem cell therapy solutions for patients in Denver, Colorado, and the surrounding cities. This regenerative medicine practice focuses on helping patients struggling …

New York, New York

Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors | PRWeb | 10/9/2020

… Patient Rated Pain Management Practice by Find Local Doctors Share Article Find Local Doctors has recently recognized Caliber Pain in New York City as a 2020 Top Patient Rated NYC Doctor for the practice’s large … highly-qualified and reputable. Caliber Pain offers interventional treatments and regenerative medicine for a wide variety of injuries and pain issues and are committed to using a multidisciplinary approach to treating patients. They focus on …

State of New York

Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors | PRWeb | 10/9/2020

… Patient Rated Pain Management Practice by Find Local Doctors Share Article Find Local Doctors has recently recognized Caliber Pain in New York City as a 2020 Top Patient Rated NYC Doctor for the practice’s large … highly-qualified and reputable. Caliber Pain offers interventional treatments and regenerative medicine for a wide variety of injuries and pain issues and are committed to using a multidisciplinary approach to treating patients. They focus on …

York, Pennsylvania

Caliber Pain is Featured as a 2020 Top NYC Patient Rated Pain Management Practice by Find Local Doctors | PRWeb | 10/9/2020

… Rated Pain Management Practice by Find Local Doctors Share Article Find Local Doctors has recently recognized Caliber Pain in New York City as a 2020 Top Patient Rated NYC Doctor for the practice’s large volume … highly-qualified and reputable. Caliber Pain offers interventional treatments and regenerative medicine for a wide variety of injuries and pain issues and are committed to using a multidisciplinary approach to treating patients. They focus on …

San Diego, California

Should California invest $5.5 billion more into promising stem cell research? | The Mercury News | 10/11/2020

… funded by Proposition 71. “It completely changed the trajectory of my life,” said Javier, of San Ramon. Sandra Dillon, a San Diego graphic designer diagnosed at age 28 with a rare form of blood cancer … more than 60 other clinical trials, the California Institute for Regenerative Medicine (CIRM) created under Proposition 71 has led to about 3,000 peer-reviewed research papers and 974 patents or patent applications. It has helped …

State of Texas

3D Bioprinting 101: Making bioprinting more accessible | 10/4/2020

Recent developments in hydrogel chemistries, reinforcement approaches, and crosslinking methods have expanded the applications of 3D bioprinting to pharmaceutics, regenerative medicine, and biomedical devices. A multitude of 3D bioprinting techniques have been developed, but among … field. To resolve this obstacle, Dr. Akhilesh Gaharwar’s lab at Texas A&M University has published a review in Tissue Engineering: Part A ( “Bioprinting 101: Design, Fabrication, and Evaluation of Cell-Laden 3D Bioprinted Scaffolds …

State of Colorado

Breaking Ground on the Medical Office Building in Basalt, Colorado | 10/8/2020

… musculoskeletal care in the Roaring Fork Valley Photo taken at the ceremonial groundbreaking for the Medical Office Building in Basalt, Colorado. Pictured left to right: Will Cook, CEO, Vail Health; Dave Ressler, CEO, Aspen Valley … services. Steadman Philippon Research Institute (SPRI) will also maintain a regenerative medicine laboratory, conference space and offices focused on orthopaedics and healthy aging research. In early September, The Steadman Clinic and Orthopedic Care Partners announced …

State of Florida

Publisher Correction: A protein assembly mediates Xist localization and gene silencing | Business Wire | 10/2/2020

… of Illinois at Chicago, Chicago, IL, USA Bernadett Papp Present address: Department of Oral Biology, College of Dentistry, University of Florida, Gainesville, FL, USA Chun-Kan Chen Present address: Center for Personal Dynamic Regulomes, Stanford … L. Black & Kathrin Plath Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, CA, USA Kathrin Plath …

Los Angeles, California

LA Times Runs Down the Middle in News Report on $5.5 Billion Stem Cell Ballot Initiative | 10/10/2020

… Times Runs Down the Middle in News Report on $5.5 Billion Stem Cell Ballot Initiative California’s largest circulation newspaper, the Los Angeles Times , this week published an overview of the state’s $5.5 billion stem cell … stem cell agency, known officially as the California Institute for Regenerative Medicine (CIRM) and which will be closing its doors this winter because it is running out of money. The measure would also substantially widen …

State of Washington

ARM and NAMCP Publish Recommendations to Increase Patient Access in Joint Study, Roadmap for Navigating the Provider Side of Cell and Gene Therapy (CGT) Patient Access in US Managed Care | Globe Newswire | 10/12/2020

Washington, DC, Oct. 12, 2020 (GLOBE NEWSWIRE) – via NewMediaWire – Reducing payment and reimbursement barriers is the most important factor in driving provider uptake of cell and gene therapies, the Alliance for Regenerative Medicine (ARM) and the National Association of Managed Care Physicians (NAMCP) Medical Directors Institute concluded in a joint study announced today. The study – “Roadmap for Navigating the Provider Side of Cell and Gene Therapy Patient Access in U.S …

Boston, Massachusetts

Assistant Professor | 10/7/2020

Boston University, Department of Biomedical Engineering Position ID: Boston, Massachusetts 02215, United States [ map ] Subject Area: (posted 2020/10/07, listed until 2020/12/18) Position Description: Apply The College of Engineering at Boston University has embarked on a … whose interests are in cellular therapeutics for applications including immunoengineering, regenerative medicine, and bioprocessing. Candidates would likely form bridges between BME and collaborative departments and centers including ME and the University’s National Emerging Infectious Disease …

State of Georgia

Robert E. Windsor, MD, is being recognized by Continental Who’s Who | PR Newswire | 9/21/2020

Robert E. Windsor, MD, is being recognized by Continental Who’s Who ALPHARETTA, Ga., Robert E. Windsor , MD, is being recognized by Continental Who’s Who as a Distinguished Leader for his remarkable contributions in the field of Medicine and for his dedication and commitment as the President, Medical Director, and Regenerative Medicine Specialist at Georgia RegenRX. Continue Reading (PRNewsfoto/Continental Who’s Who) Located in the greater Atlanta area at 5755 North …

Chicago, Illinois

The Histone Demethylase KDM3B Promotes Osteo-/Odontogenic Differentiation, Cell Proliferation, and Migration Potential of Stem Cells from the Apical Papilla | 10/7/2020

… the osteo-/odontogenic differentiation, cell proliferation, and migration potential of SCAPs and provided a novel target and theoretical basis for regenerative medicine. 1. Introduction With the development of the technique, the treatment outcome of tooth … data were analyzed by the SPSS17 statistical software (SPSS Inc., Chicago, IL, USA). Significance was determined using Student’s - test. was regarded as statistically significant. 3. Results 3.1. KDM3B Increased the Osteo-/Odontogenic Differentiation Potential of …

San Francisco, California

Opinion: The Post’s recommendations on the 12 ballot propositions and Measure RR | 10/13/2020

… accountability. Caltrain’s board is appointed by officials in San Mateo County even though the railroad also serves Santa Clara and San Francisco counties. In fact, the CEO of Caltrain — currently former Redwood City politician Jim … of $5.5 billion in bonds for the California Institute of Regenerative Medicine, now that the agency has exhausted the original $3 billion it got from taxpayers 16 years ago. The original purpose of the agency …

State of Massachusetts

Survey finds American support for human-animal chimera research | 10/1/2020

… introducing human pluripotent stem cells into animal embryos—a practice that experts say is vital for advancing the field of regenerative medicine. To assess attitudes on human-animal chimeric embryo research, investigators conducted a survey … the University of Minnesota and executive director of the Harvard Massachusetts General Hospital Center for Law, Brain, and Behavior. “I think this speaks to the public’s interest in the transformative potential of regenerative medicine for …

State of Illinois

Publisher Correction: A protein assembly mediates Xist localization and gene silencing | Business Wire | 10/2/2020

… of California San Francisco, San Francisco, CA, USA Constantinos Chronis Present address: Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, USA Bernadett Papp Present address: Department of Oral Biology, College … L. Black & Kathrin Plath Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, CA, USA Kathrin Plath …

Dublin, California

Global Regenerative Medicine Partnering Terms and Agreements 2014-2020: Company A-Z, Headline Value, Stage of Development, Deal component, Specific Therapy Target, Technology Type | Globe Newswire | 9/24/2020

September 24, 2020 05:04 ET Source: Research and Markets Dublin, Sept. 24, 2020 (GLOBE NEWSWIRE) – The “Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020” report has been added to ResearchAndMarkets.com’s offering. The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by …

State of Indiana

(Podcast) Functional Family Medicine SPOTLIGHT: Meet Dr. Daniel Stock | 10/12/2020

Dr. Dan Stock, A founding diplomate of the American Board of Clinical Lipidology, Dr. Stock is also a diplomate of the American Board of Anti-Aging and Regenerative Medicine. By We sit down with Dr. Daniel Stock, the Founding Physician at PureHealth Functional Family Medicine. Dr. Stock’s office is located in Noblesville, Indiana. After 18 years of being hospital-employed, Dr. Daniel Stock has opened the doors to his new …

Pittsburgh, Pennsylvania

NIH Renews Funding for Science and Regenerative Medicine Research | 7/14/2020

Posted by Debbie Overman Jul 14, 2020 Association News 0 The National Institutes of Health (NIH) has renewed a five-year grant for $5 million for the Alliance for Regenerative Rehabilitation and Training (AR 3 T) to continue its work expanding scientific knowledge, expertise and methodologies focused on science and regenerative medicine. AR 3 T is a multi-institutional network of laboratories at the University of Pittsburgh , Stanford University , Mayo …

State of North Carolina

Atrium Health and Wake Forest Baptist Health Combine, Create Next-Generation Academic Health System | PR Newswire | 10/9/2020

North Carolina as a clear destination of choice to receive medical care for people all across the nation,” said Dr. Julie Ann Freischlag , CEO of Wake Forest Baptist Health and dean of Wake Forest School of Medicine. Through our combined, nationally recognized clinical centers of excellence in multiple specialties, we will be able to expand our research in signature areas, such as cancer, cardiovascular, regenerative medicine and aging, and target …

Washington, District of Columbia

ARM and NAMCP Publish Recommendations to Increase Patient Access in Joint Study, Roadmap for Navigating the Provider Side of Cell and Gene Therapy (CGT) Patient Access in US Managed Care | Globe Newswire | 10/12/2020

Washington, DC, Oct. 12, 2020 (GLOBE NEWSWIRE) – via NewMediaWire – Reducing payment and reimbursement barriers is the most important factor in driving provider uptake of cell and gene therapies, the Alliance for Regenerative Medicine (ARM) and the National Association of Managed Care Physicians (NAMCP) Medical Directors Institute concluded in a joint study announced today. The study – “Roadmap for Navigating the Provider Side of Cell and Gene Therapy Patient Access in U.S …

State of Iowa

Post Falls-based stem cell purveyors face lawsuits by attorneys general in two states - Tue, 15 Sep 2020 PST | 9/15/2020

Iowa and Nebraska for what they say are false claims about the benefits of the injections. The civil lawsuits have been filed against owners Travis and Emily Autor, who until recently lived in Liberty Lake, and company executive Mike Pavey, of Spokane. The civil suits allege Stem Cell Centers, which also does business as NW Regenerative Medicine, is essentially defrauding patients by failing to provide the promised cures. “This lawsuit …

Omaha, Nebraska

Attorney Generals file lawsuits against owners of stem cell therapy clinics | 7/17/2020

Omaha Stem Cells, LLC, Regenerative Medicine and Anti-Aging, Stem Cell Centers, LLC and the owners Travis and Emily Autor of consumer fraud. CLICK HERE TO READ THE FULL COMPLAINT”It made incredibly on strong claims about dealing with back pain and arthritis, but they went beyond that, they make claims that they could reverse COPD, to some extent,” Miller said. The defendants also promised to treat osteoarthritis, neuropathy and …

State of Nebraska

Post Falls-based stem cell purveyors face lawsuits by attorneys general in two states - Tue, 15 Sep 2020 PST | 9/15/2020

Nebraska for what they say are false claims about the benefits of the injections. The civil lawsuits have been filed against owners Travis and Emily Autor, who until recently lived in Liberty Lake, and company executive Mike Pavey, of Spokane. The civil suits allege Stem Cell Centers, which also does business as NW Regenerative Medicine, is essentially defrauding patients by failing to provide the promised cures. “This lawsuit … seeks a …